Core Insights - Alcon reported revenue of $2.45 billion for Q1 2025, a year-over-year increase of 0.3%, with EPS of $0.73 compared to $0.78 a year ago, missing the Zacks Consensus Estimate of $2.51 billion by -2.32% and EPS estimate by -3.95% [1] Financial Performance - The company's net sales by region included $1.31 billion in international sales, slightly below the $1.39 billion estimate, reflecting a year-over-year increase of 1.5% [4] - In the United States, net sales reached $1.14 billion, exceeding the $1.12 billion estimate [4] - Total Surgical net sales were $1.33 billion, below the $1.38 billion estimate, showing a year-over-year decline of 0.5% [4] - Total Vision Care net sales were $1.12 billion, slightly below the $1.14 billion estimate, with a year-over-year increase of 1.3% [4] Segment Performance - Total Surgical Consumables generated $712 million, compared to the $717.01 million estimate, marking a year-over-year increase of 3.8% [4] - Total Surgical Equipment/Other sales were $199 million, below the $223.04 million estimate, reflecting a year-over-year decline of 9.1% [4] - Total Vision Care Contact Lenses sales were $688 million, slightly below the $693.41 million estimate, with a year-over-year increase of 2.5% [4] - Total Vision Care Ocular Health sales were $432 million, below the $441.87 million estimate, showing a year-over-year decline of 0.7% [4] - Total Surgical Implantables sales were $420 million, below the $435.74 million estimate, reflecting a year-over-year decline of 3% [4] - Other revenues reached $22 million, exceeding the $17.50 million estimate, with a significant year-over-year increase of 46.7% [4] Stock Performance - Alcon's shares returned +4.7% over the past month, compared to the Zacks S&P 500 composite's +9.1% change, with a current Zacks Rank of 3 (Hold), indicating potential performance in line with the broader market [3]

Financial Performance - Q4 2024 sales reached $2.5 billion, a 6% increase year-over-year on a reported and constant currency basis[15] - Q4 2024 operating margin was 15.9%, up 700 basis points year-over-year[15] - Q4 2024 core operating margin was 20.1%, up 120 basis points year-over-year[15] - Q4 2024 diluted EPS was $0.57, down 34% year-over-year[15] - Q4 2024 core diluted EPS was $0.72, up 3% year-over-year[15] - FY24 free cash flow was $1.6 billion, compared to $0.7 billion in FY23[15] - FY24 sales reached $9.8 billion, a 5% increase year-over-year[20,35] - FY24 diluted EPS was $2.05, a 5% increase year-over-year[35] - FY24 core diluted EPS was $3.05, a 16% increase year-over-year on a constant currency basis[49] Segment Performance - Vision Care sales were $4.3 billion, representing 44% of FY24 sales[21] - Surgical sales were $5.5 billion, representing 56% of FY24 sales[21] FY 2025 Outlook - The company projects net sales of $10.2 to $10.4 billion, representing a 6% to 8% increase on a constant currency basis[63] - The company projects a core operating margin of 21% to 22%[63] - The company projects a core diluted EPS of $3.15 to $3.25, representing an 8% to 11% increase on a constant currency basis[63]